1. Genetics and Genomics

Characterization of caffeine response regulatory variants in vascular endothelial cells

  1. Carly Boye
  2. Cynthia A Kalita
  3. Anthony S Findley
  4. Adnan Alazizi
  5. Julong Wei
  6. Xiaoquan Wen
  7. Roger Pique-Regi  Is a corresponding author
  8. Francesca Luca  Is a corresponding author
  1. Center for Molecular Medicine and Genetics, Wayne State University, United States
  2. Department of Biostatistics, University of Michigan, United States
  3. Department of Obstetrics and Gynecology, Wayne State University, United States
  4. Department of Biology, University of Rome Tor Vergata, Italy
https://doi.org/10.7554/eLife.85235
Share this article
Cite this article
  1. Carly Boye
  2. Cynthia A Kalita
  3. Anthony S Findley
  4. Adnan Alazizi
  5. Julong Wei
  6. Xiaoquan Wen
  7. Roger Pique-Regi
  8. Francesca Luca
(2024)
Characterization of caffeine response regulatory variants in vascular endothelial cells
eLife 13:e85235.
https://doi.org/10.7554/eLife.85235
  2. Download BibTeX
  3. Download .RIS

Abstract

Genetic variants in gene regulatory sequences can modify gene expression and mediate the molecular response to environmental stimuli. In addition, genotype–environment interactions (GxE) contribute to complex traits such as cardiovascular disease. Caffeine is the most widely consumed stimulant and is known to produce a vascular response. To investigate GxE for caffeine, we treated vascular endothelial cells with caffeine and used a massively parallel reporter assay to measure allelic effects on gene regulation for over 43,000 genetic variants. We identified 665 variants with allelic effects on gene regulation and 6 variants that regulate the gene expression response to caffeine (GxE, false discovery rate [FDR] < 5%). When overlapping our GxE results with expression quantitative trait loci colocalized with coronary artery disease and hypertension, we dissected their regulatory mechanisms and showed a modulatory role for caffeine. Our results demonstrate that massively parallel reporter assay is a powerful approach to identify and molecularly characterize GxE in the specific context of caffeine consumption.

Editor's evaluation

This important study identifies context-specific regulatory variants by an MPRA screen in vascular endothelial cells exposed to caffeine. The authors use a compelling and creative approach to pinpoint potential molecular mechanisms of gene-by-environment effects on gene regulation. The variants they identify are likely linked to complex disease risk.

https://doi.org/10.7554/eLife.85235.sa0

Introduction

Caffeine is the most widely consumed stimulant in the world (Planning Committee for a Workshop on Potential Health Hazards Associated with Consumption of Caffeine in Food and Dietary Supplements, Food and Nutrition Board, Board on Health Sciences Policy, Institute of Medicine, 2014). Caffeine produces a vascular response in the endothelium, causing vasodilation. The vascular endothelium, the innermost layer of arteries, is involved in several important functions, including regulation of blood flow, angiogenesis, thrombosis, and coagulation (Hadi et al., 2005; Krüger-Genge et al., 2019). Endothelial dysfunction occurs in diseases such as atherosclerosis and hypertension (Xu et al., 2021), eventually leading to coronary artery disease (CAD) (Matsuzawa and Lerman, 2014). Multiple studies have investigated the role of caffeine in cardiovascular disease (CVD), and more broadly, vascular health in general, with conflicting results (Chieng et al., 2022; Ding et al., 2014; Turnbull et al., 2017) on the role of caffeine in CVD risk. Ding et al., 2014 meta-analyzed 36 studies and found no association between heavy coffee consumption and increased risk of CVD (Ding et al., 2014). Similarly, Turnbull et al., 2017 observed that moderate caffeine consumption was not associated with an increased risk of CVD or other cardiovascular events such as heart failure (Turnbull et al., 2017). Multiple studies suggested that caffeine may be beneficial in reducing the risk of CAD (Choi et al., 2015; Miranda et al., 2018; Voskoboinik et al., 2019), while others provided evidence that caffeine may reduce the risk of heart failure, but had no significant effect on the risk of coronary heart disease or CVD (Stevens et al., 2021). Most recently, Chieng et al., 2022 found that decaffeinated, ground, and instant coffee significantly decreased CVD risk and mortality (Chieng et al., 2022). The conflicting results from these epidemiological studies may have several causes, including potential interactions between caffeine consumption and other environmental and genetic risk factors. Recent molecular studies investigated the consequences of caffeine exposure on chromatin accessibility and gene expression in vascular endothelial cells (Findley et al., 2019). This study identified response factor motifs for caffeine, defined as transcription factor motifs that are enriched in differentially accessible regions, and demonstrated that caffeine can induce changes in gene regulation in endothelial cells.

Analyzing the changes in gene expression upon exposure to environmental stimuli is a powerful approach to discover genotype–environment interactions (GxE). These molecular GxE result in a different response depending on genotype (Knowles et al., 2018; Knowles et al., 2017; Moyerbrailean et al., 2016b), potentially through allele-specific effects (ASE) on response factor binding or other environmental-specific gene regulatory mechanisms. Yet regulatory sequences that are differentially bound in response to environmental perturbations are poorly annotated. Single-nucleotide polymorphisms (SNPs) within caffeine response factor binding sites were enriched for artery expression quantitative trait loci (eQTLs) colocalized with CAD risk variants (Findley et al., 2019). The results of this study thus suggested that SNPs within regulatory elements active in the presence of caffeine may play a role in CAD risk and pointed to GxE in gene regulation as a potential mechanism underlying caffeine modulation of genetic risk for CAD. However, only a limited number of molecular GxE for caffeine have been studied so far, thus the transcription factors and regulatory sequences involved in caffeine GxE remain uncharacterized. Furthermore, it is important to study GxE in the relevant cell type; that is, endothelial cells which constitute the vascular endothelium. For these reasons, it is crucial to investigate and validate the mechanisms behind caffeine GxE in vascular endothelial cells.

Massively parallel reporter assays (MPRA) have allowed studies of noncoding genetic variants and their role in gene regulation, at unprecedented scale (Arnold et al., 2013; Gordon et al., 2020; Kalita et al., 2018; Melnikov et al., 2012; Patwardhan et al., 2012; Tewhey et al., 2016; Ulirsch et al., 2016; Vockley et al., 2015; Wang et al., 2018). Originally developed to study the gene regulatory potential of promoters and enhancer sequences, MPRA protocols have been further developed to study regulatory genetic variation and fine map association signals (Kalita et al., 2018; Tewhey et al., 2016; Ulirsch et al., 2016; Vockley et al., 2015). MPRAs with synthetic regulatory sequences can test allelic activity for candidate regulatory variants independently of their allele frequency in the population (Kalita et al., 2018; Tewhey et al., 2016; Ulirsch et al., 2016; Vockley et al., 2015). In MPRAs, DNA sequences containing each allele are transfected into cells and RNA-seq is used to quantify the transcripts for each allele. To directly test allelic effects of tens of thousands of candidate regulatory sequences predicted to affect transcription factor binding (CentiSNPs; Moyerbrailean et al., 2016a), we used an MPRA called Biallelic Targeted STARR-Seq (BiT-STARR-Seq) (Kalita et al., 2018). Only two previous studies have used MPRAs to investigate DNA sequences that regulate the transcriptional response to treatments (Johnson et al., 2018; Shlyueva et al., 2014). One study utilized STARR-Seq to characterize enhancer activity in Drosophila cells upon treatment with the hormone ecdysone; however, it did not investigate GxE (Shlyueva et al., 2014). The other study utilized STARR-Seq to investigate the response to glucocorticoid treatment in the human cell line A549 (Johnson et al., 2018). Although this study investigated GxE interactions, only a small number of variants were tested as this study was limited to preexisting variation within the samples (as opposed to designed target sequences) and only two variants had significant GxE (Johnson et al., 2018). We aim to identify and validate the DNA sequences that regulate the transcriptional response to caffeine in the vascular endothelium and how genetic variation present in these regulatory elements may affect the transcriptional response to caffeine (Figure 1A).

Figure 1 with 1 supplement see all
Download asset Open asset
Study design.

(A) Genetic variants modulate transcriptional response dependent on environmental conditions. The pink bars represent different alleles present in our targets, and the green triangle represents a bound transcription factor. These target sequences are transfected into cells, RNA is extracted and sequenced, and then activity is measured for targets for both alleles. (B) Library composition based on annotation category: single-nucleotide polymorphisms (SNPs) predicted to alter transcription factor binding using a combination of sequence information and experimental data (centiSNPs) (Moyerbrailean et al., 2016b), SNPs associated with complex traits (genome-wide association studies [GWAS]), and expression quantitative trait loci (eQTL) in GTEx.

Results

Active regulatory regions in response to caffeine

For this study, we used a library of targets that was designed to capture a large number of predicted gene regulatory variants in motifs for hundreds of transcription factor binding sites (Figure 1B). The targets in our library consisted of self-transcribing enhancer regions containing a minimal promoter, a reporter gene, and the oligonucleotide containing the candidate regulatory SNP. These candidate regulatory SNPs belong to multiple categories, including SNPs predicted to alter transcription factor binding using a combination of sequence information and experimental data (centiSNPs) (Moyerbrailean et al., 2016b), SNPs associated with complex traits (genome-wide association studies [GWAS]), and eQTLs in GTEx. In addition, we included 1676 negative control sequences. To test if these putative regulatory sequences mediate the response to caffeine, we used DESeq2 to test for differential activity of the targets in cells treated with caffeine compared to cells in the control group (see ‘Materials and methods’ for the specific model). The library contained motifs in both the forward and reverse orientations within separate targets. Since these motifs may induce direction-specific effects, we performed the differential activity analysis per each direction separately (see Figure 2—figure supplement 1; see also Figure 2—figure supplements 2 and 3), and considered any target with false discovery rate (FDR) < 10% in either direction as significant. We observed 772 significantly differentially active targets: 546 upregulated targets and 226 downregulated targets (Figure 2A, Supplementary file 1), showing that caffeine overall increases the activity of the regulatory elements.

Figure 2 with 3 supplements see all
Download asset Open asset
Active regulatory regions in caffeine response in vascular endothelial cells.

(A) Volcano plot for DESeq2 results showing targets differentially active in caffeine. The light red points are significant (false discovery rate [FDR] < 10%) targets containing caffeine response factor binding sites, the black points are significant targets not containing a caffeine response factor binding site, and the gray points are nonsignificant targets. The inset contains a QQ plot for targets containing a caffeine response factor binding site (red), or no caffeine response factor binding site (black). (B) Motifs enriched via test of proportions (p<0.05) within differentially active targets. Names of caffeine response factors are bolded. For B-D panels error bars represent the 95% confidence interval (motif occurrence, n >100). (C) Motifs enriched via test of proportions within upregulated targets (p<0.05). (D) Motifs enriched via test of proportions within downregulated targets (p<0.05).

We then focused on differentially active targets containing a known caffeine response factor as determined based on chromatin accessibility data from endothelial cells treated with caffeine (Findley et al., 2019). We observed that these targets had lower p-values, as observed in the QQ plot in Figure 2A (inset). To identify any additional transcription factors that may be important for the response to caffeine, we conducted a motif scan for 838 known transcription factor binding motifs using the JASPAR CORE Vertebrates 2022 database (Castro-Mondragon et al., 2022; Supplementary file 2). We found 19 motifs that were enriched for being within differentially active targets (Figure 2B, Supplementary file 3). We found the motif for ZNF423, one of the caffeine response factors, was enriched within the differentially active targets. The three most enriched motifs were NFATC1, NFATC4, and NFATC2. The NFAT transcription factor family is known for their involvement in the Ca2+/NFAT pathway. This signaling pathway plays an important role in maintaining the homeostasis of vascular endothelial cells (Wang et al., 2020) and contributes to the mediation of proliferation and migration (Johnson et al., 2003; Wang et al., 2020). Thus, improper signaling of the Ca2+/NFAT pathway can induce endothelial dysfunction (Garcia-Vaz et al., 2020; Wang et al., 2020). In diabetic mice, NFAT expression exacerbated atherosclerosis (Blanco et al., 2018; Zetterqvist et al., 2014) and increased foam cell formation (Du et al., 2021). In human coronary artery smooth muscle cells, NFAT signaling mediates vascular calcification (Goettsch et al., 2011). To better understand the regulatory response to caffeine, we then investigated which motifs were enriched for being within upregulated or downregulated targets separately (Supplementary file 3). We observed 19 motifs enriched for being within upregulated targets (Figure 2C) and 23 motifs enriched for being within downregulated targets (Figure 2D). Motifs enriched for being within upregulated targets include the previously mentioned NFATC1 and ZNF423. Motifs enriched for being within downregulated targets include the previously mentioned NFATC2 and ZNF423. We also observed that the motif for SREBF2, also called SREBP2, is enriched for being within downregulated targets. In hepatocytes, caffeine is known to suppress SREBF2 activity, which reduces PCSK9 expression, and thus increases LDLR expression, which could be protective against CVD (Lebeau et al., 2022). The corresponding transcription factors for these motifs could also play a role in mediating the response to caffeine in vascular endothelial cells. The motif for TEAD4 was also identified as enriched for being within downregulated targets. Interestingly, a CAD GWAS risk variant disrupts binding of TEAD4 in smooth muscle cells, causing lower expression of p16, which could potentially contribute to the risk identified at this locus (Almontashiri et al., 2015).

Allelic effects on gene regulation within conditions and in response to caffeine

To investigate how genetic variation affects regulatory sequences and their function in cells treated with caffeine and in the control samples, we tested for ASE. Since the library contained the same sequence in both the forward and reverse orientations in independent targets and the regulatory effect may be direction-dependent, we tested for ASE in each SNP/direction pair separately (Supplementary file 4; Figure 3—figure supplement 1, see ‘BiT-STARR-Seq Library Design’ section for a more detailed description of terminology used). We observed 689 SNP/direction pairs (corresponding to 665 SNPs) with significant ASE out of 50,914 SNP/direction pairs (30,680 SNPs) tested (2.2%, FDR < 10%) (Figure 3A). Additionally, our library contained negative control sequences that were predicted to not have an allelic regulatory effect. These negative control sequences tend to have higher p-values than other sequences in our library, as predicted (Figure 3A). These results demonstrate that genetic variation within regulatory sequences within our library can modulate gene expression levels in vascular endothelial cells.

Figure 3 with 3 supplements see all
Download asset Open asset
Allelic effects on gene regulation within conditions and in response to caffeine.

(A) QQ plot depicting the p-values for allele-specific effects (ASE), with negative control sequences labeled in lighter red (caffeine) or lighter blue (control). (B) QQ plot depicting the p-values for conditional allele-specific effects (cASE), with targets containing caffeine response factor motifs annotated in pink and all other sequences in blue. (C) Enrichment via Fisher’s exact test (p<0.05) of ASE (green) and cASE (purple) variants in open chromatin regions and targets containing artery expression quantitative trait loci (eQTL). Error bars indicate 95% confidence intervals. The sample sizes for each test are reported in Supplementary file 3.

To directly test for GxE in the molecular response to caffeine, we tested for conditional allele-specific effects (cASE), where ASE is only significant in one condition, or significantly different between the two conditions. When testing for cASE, we observed 6 significant SNP/direction pairs (corresponding to 6 SNPs) out of 23,814 (15,927 SNPs) tested (FDR < 5%) (Figure 3B, Supplementary file 4, Figure 3—figure supplement 2). Additionally, we annotated which of these cASE targets contains a known caffeine response factor as defined in Findley et al., 2019, based on ATAC-seq data. There is an enrichment for these targets containing caffeine response factors, as expected (Figure 3B). The size of this enrichment may be underestimated due to the relatively small amount of caffeine response factor motifs (4) present in the designed library. Importantly, these variants contribute to inter-individual variation in response to caffeine. Thus, we sought to further characterize these variants.

To investigate the regulatory architecture underlying these genetic effects on gene expression, we asked whether ASE (FDR < 10%) and cASE variants (here defined at a nominal p<0.0215, N = 569) were enriched in open chromatin regions as annotated in Findley et al., 2019. ASE variants were 2.4-fold enriched within open chromatin regions (p<2.2e-16, Figure 3C, green), while a more moderate trend was observed for cASE (1.2-fold, p=0.088, Figure 3C, purple). This difference in enrichment could be due to the difference between the native chromatin context versus the reporter assay context. Environmental effects on gene regulatory sequences may have a more complex regulatory architecture influenced by the chromatin context that may explain the difference in the enrichment results between ASE and cASE (Supplementary file 3).

Genetic regulation of gene expression can be context-dependent, with factors such as cell type (Donovan et al., 2020; Kim-Hellmuth et al., 2020), developmental states (Cuomo et al., 2020; Strober et al., 2019), and environmental stimuli all contributing to GxE (GxE-eQTLs, also known as response eQTLs, dynamic eQTLs, context-eQTLs) (e.g., see Alasoo et al., 2019; Barreiro et al., 2012; Çalışkan et al., 2015; Findley et al., 2021; Kim-Hellmuth et al., 2017; Maranville et al., 2011; Moyerbrailean et al., 2016b). These context-specific effects can be captured without large cohorts if the appropriate experimental design is applied (Findley et al., 2021). Allele-specific expression experiments in two different conditions can detect GxE in small sample sizes compared to eQTL studies (Moyerbrailean et al., 2016b). To investigate the abundance of GxE missing from large databases such as GTEx (Consortium, 2020), we tested if cASE variants were enriched for artery eQTLs. Using variants within the open chromatin regions described above, we conducted a Fisher’s exact test and found that ASE variants were 1.38 times more likely to be artery eQTLs (p=0.01, Figure 3C, green) compared to variants that did not show ASE. We observed a more moderate trend for cASE variants (1.2 times more likely to be artery eQTLs, p=0.26, Figure 3C, purple, Supplementary file 3).

Characterizing ASE and cASE across transcription factor motifs

We hypothesized that the regulatory context defined by the transcription factor motifs present in each target determines the effect of a genetic variant on expression in caffeine treated cells. We conducted a motif scan of the library of targets for 838 known transcription factor binding motifs from JASPAR (Castro-Mondragon et al., 2022; Supplementary file 2). We then used a test of proportions to identify any motifs that were disproportionately within targets containing significant ASE or cASE variants. For targets containing ASE variants, we observed 44 enriched motifs (Figure 4). For targets containing cASE variants, we observed 18 enriched motifs (Figure 4, Supplementary file 3 ). Factors of interest for cardiovascular function include NRF1, enriched for targets containing cASE and ASE variants, which is known to regulate lipid metabolism (Hirotsu et al., 2012; Huss and Kelly, 2004), and is annotated as part of the lipid metabolism pathway in Reactome (Fabregat et al., 2018). KLF15 and KLF14 are also enriched in targets with cASE and ASE. KLF15 is involved in cardiac lipid metabolism (Prosdocimo et al., 2014; Prosdocimo et al., 2015), and KLF14 has previously been associated with CVD (Fryar et al., 2012; Hu et al., 2018). Lastly, SREBF2, which was identified as enriched within our differential activity results, also has implications for disease as discussed previously. This implies that SREBF2 are important both in the interindividual response to caffeine as well as disease state, linking our identified GxE with atherosclerotic disease.

Figure 4
Download asset Open asset
Transcription factors contributing to allele-specific effect (ASE) and conditional allele-specific effect (cASE).

Motifs enriched via test of proportions (p<0.05) for significant ASE (green) or cASE (purple). The dotted lines represent the baseline proportion (mean number of significant variants within any motif) for ASE (green) and cASE (purple). Bolded factors are caffeine response factors as defined in Findley et al., 2019. Error bars represent the 95% confidence interval, motif occurrence n>100.

We also wanted to investigate if ASE and cASE variants were disproportionately present in caffeine response factor binding sites, which may indicate that caffeine response factors’ regulatory function may be modified by genetic variation. For this analysis, we used annotations from Findley et al., 2019, which defines caffeine response factors as transcription factors with motifs that were significantly enriched or depleted in differentially accessible chromatin after treatment with caffeine. Factors INSM1 and PLAG1 are caffeine response factors as defined in Findley et al., 2019, confirming that genetic variation may modulate the response to caffeine by increasing binding activity of these transcription factors.

Validation of the regulatory mechanism for fine-mapped artery eQTLs

Computational fine-mapping is a commonly used method to identify causal variants, often for complex traits; however, further functional validation is usually needed to confirm the regulatory mechanism underlying fine-mapped causal variants. We previously showed that artery eQTLs are enriched in caffeine response factor motifs (also see Figure 3—figure supplement 3; Findley et al., 2019). We now leverage this finding to fine-map artery eQTLs using DAP-G and the caffeine response factor annotation from Findley et al., 2019. In our library, we tested 187 fine-mapped variants. We identified significant ASE for six SNPs (six SNP/direction pairs), thus validating the regulatory function of these fine-mapped causal eQTLs (Supplementary file 5). We also identified two fine-mapped artery eQTLs with significant cASE (p<0.0215; 2 SNP/direction; Supplementary file 5), which may represent hidden GxE in GTEx.

We then investigated if the genes shown to be linked to CAD and hypertension risk using both TWAS and colocalization analysis (INTACT, Okamoto et al., 2023) can be further modulated by GxE with caffeine. INTACT combines TWAS and colocalization approaches, thus overcoming the TWAS inherent linkage disequilibrium limitations. We identified eight cASE variants that regulate the expression of genes associated with CAD and hypertension (<10% FDR for INTACT analysis, p<0.0215 for cASE analysis, Supplementary file 6). We used available experimental data and computational predictions to dissect the regulatory mechanisms underlying context-specific allelic effects for two of these SNPs and their impact on CAD risk (Figures 5 and 6). We considered allelic effects on transcription factor binding, expression of the transcription factors, and disease risk. Specifically, we considered (i) predicted effects on transcription factor binding from CentiSNP, which uses a combination of sequence information and chromatin accessibility data to predict alleles that increase binding of specific transcription factors (Moyerbrailean et al., 2016a); (ii) changes in the expression of the genes encoding for the relevant transcription factors and changes in chromatin accessibility (Findley et al., 2019); and (iii) allelic effect on the target genes (this study and GTEx).

Figure 5
Download asset Open asset
Example genetic variant with GxE with caffeine where caffeine may increase genetic risk of CAD.

(A) Potential mechanism for rs4938344. (B) Transcription factors containing rs4938344 in a binding site are upregulated (via DESeq2) upon caffeine exposure (error bars are +/- standard error, FDR<10%, n=14). (C) Logos of transcription factor motifs with rs4938344 highlighted. (D) GTEx violin plot for AP000892.6. (E) Effect size from the BiT-STARR-Seq assay for this single-nucleotide polymorphism (SNP) within each condition (error bars are +/- standard error, n=4 replicates per condition, cASE p<0.0215, see ‘cASE Analysis’ section of methods). (F) Locus zoom plots showing genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data for hypertension (left) and coronary artery disease (CAD) (right) in tibial artery tissue.

Figure 6
Download asset Open asset
Example genetic variant with GxE with caffeine where caffeine may decrease genetic risk of CAD.

(A) Potential mechanism for rs4527034. (B) TERF2IP is upregulated (via DESeq2) upon caffeine exposure (error bars are +/- standard error, FDR<10%, n = 14). (C) Logos of TERF2IP motif with rs4527034 highlighted. (D) GTEx violin plot for KAT8. (E) Effect size from the BiT-STARR-Seq assay for this single-nucleotide polymorphism (SNP) within each condition (error bars are +/- standard error, n=4 replicates per condition, cASE p<0.0215, see ‘cASE Analysis’ section of methods). (F) Locus zoom plots showing genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data for hypertension in coronary artery tissue.

rs4938344 is an eQTL regulating the long noncoding RNA AP000892.6. The reference allele at this locus, G, results in decreased expression of AP000892.6 (as measured in GTEx and in the caffeine condition of our assay, Figure 5D and E, respectively). INTACT associated high expression of AP000892.6 with decreased risk of hypertension and CAD (Figure 5F). This SNP is predicted to modulate binding of GABP (a known repressor of transcription; Genuario and Perry, 1996) and ETV1 at this site (Figure 5C). These transcription factors are upregulated in caffeine-exposed endothelial cells (Findley et al., 2019; Figure 5B). This increase in expression uncovers allelic differences in gene regulation which are not detected in the absence of caffeine, likely because of the low expression of the repressor. The allelic differences in binding of these factors should lead to allelic differences in the expression of AP000892.6. Accordingly, the reference allele for this variant exhibited lower activity in response to caffeine in our BiT-STARR-Seq experiments (Figure 5E). This effect is consistent with the GTEx artery eQTL for AP000892.6 (Figure 5D). In summary, caffeine induces higher expression of the ETV1 and GABP transcription factors, which then bind preferentially to the reference allele at rs4938344; this results in lower expression of AP000892.6 and increased risk for CAD and hypertension (Figure 5A). AP000892.6 interacts with the RB1CC1 RNA (Gong et al., 2018), which may play a role in atherosclerosis via its function in forming the autophagosome (Chen et al., 2021).

rs4527034 is an eQTL regulating the KAT8 gene. The reference allele at this locus, A, results in decreased expression of KAT8 (as measured in GTEx and in the control condition of our assay, Figure 6D and E, respectively). INTACT associated high expression of KAT8 with increased risk of hypertension (Figure 6F). This SNP is predicted to modulate binding of the TERF2IP transcription factor at this site (Figure 6C). TERF2IP is upregulated in caffeine-exposed endothelial cells (Findley et al., 2019; Figure 6B). This increase in expression may saturate all binding sites in the caffeine condition, while the transcription factor may only bind to the preferential allele in the control condition. The allelic differences in binding of these factors should lead to allelic differences in expression of KAT8 in the control condition, which is what we observe both in our BiT-STARR-Seq experiments (Figure 6E) and in GTEx artery eQTL for KAT8 (Figure 6D). In summary, in the absence of caffeine, TERF2IP binds preferentially to the reference allele at rs4527034, which results in lower expression of KAT8 and reduced risk for hypertension. In the presence of caffeine, TERF2IP is upregulated, resulting in increased binding and lower expression of KAT8, independently of the genotype, with an expected overall protective effect on hypertension. Confirming this potential mechanism for disease risk, TERF2IP expression levels were found to affect plaque formation in a mouse model (Kotla et al., 2019). High expression of KAT8, a histone acetyltransferase, also coincides with atherosclerotic progression, and histone acetylation increases in plaques within vascular endothelial cells (Greißel et al., 2016; Zhang et al., 2018).

Discussion

This study utilized the MPRA BiT-STARR-Seq to identify gene regulatory activity in vascular endothelial cells exposed to caffeine. By utilizing BiT-STARR-Seq, we were able to identify a molecular response to caffeine, ASE, and cASE. By combining our results with preexisting annotations, we were able to characterize variants exhibiting cASE and identify potential mechanisms for some of these variants.

Heart disease is one of the leading causes of death in the United States according to the CDC (http://wonder.cdc.gov/ucd-icd10.html). The most common type of heart disease is CAD, which affects over 18 million adults over the age of 20 y (Fryar et al., 2012). The common risk factors of CAD include hypertension, high cholesterol levels, and family history (Brown et al., 2022; Hajar, 2017). CAD occurs when plaques form in the arteries (atherosclerosis), causing a narrowing of the artery, which reduces blood flow to the heart. The innermost layer of the artery is composed of endothelial cells. The endothelium is involved in several important functions, including regulation of blood flow, angiogenesis, thrombosis, and coagulation (Hadi et al., 2005; Krüger-Genge et al., 2019). Endothelial dysfunction occurs in diseases such as atherosclerosis and hypertension (Xu et al., 2021), eventually leading to CAD (Matsuzawa and Lerman, 2014). The molecular mechanisms behind endothelial dysfunction and the resulting diseases are largely unknown. Characterizing these molecular mechanisms is crucial in order to gain a more complete understanding of these disease phenotypes. Additionally, although caffeine is known to produce a vascular response, the current literature does not come to a consensus on the role of caffeine in CAD risk. Here, we characterized the regulatory response of noncoding variants to caffeine in vascular endothelial cells using an MPRA.

BiT-STARR-Seq, the MPRA used in this study, has several advantages over other methods used to detect GxE. One common method of detecting GxE is response eQTL mapping, which includes collecting samples from large cohorts and exposing those cells to environmental perturbations (e.g., see Alasoo et al., 2019; Alasoo et al., 2018; Barreiro et al., 2012; Çalışkan et al., 2015; Fairfax et al., 2014; Huang et al., 2020; Kim-Hellmuth et al., 2017; Knowles et al., 2018; Lee et al., 2014; Mangravite et al., 2013; Manry et al., 2017; Maranville et al., 2011; Nédélec et al., 2016; Quach et al., 2016). This method has several disadvantages as it cannot easily interrogate rare variants, relies on variation existing in a cohort (instead of investigating variants of interest), and requires larger cohort sizes to have enough power to detect GxE. In contrast, because our method uses a designed library of targets (Kalita et al., 2018), we are able to interrogate rare variants easily as our targets are synthesized. Similarly, we can design a library of specific variants to investigate (such as candidate regulatory variants) instead of relying on variation within a cohort (Kalita et al., 2018). BiT-STARR-Seq also allows us to directly compare two alleles within the same sequence context without requiring a large cohort. Despite the advantages of BiT-STARR-Seq, unlike response eQTL mapping, we are not interrogating these SNPs in their native chromatin context. Future work may include using genome-editing tools such as CRISPR to directly insert the desired variants in their endogenous locations in the genome. For our study, we determined BiT-STARR-Seq to be the ideal assay to determine GxE for a large number of SNPs.

We observed a regulatory response to caffeine treatment, consistent with previous studies in the same cell type (Findley et al., 2019; Moyerbrailean et al., 2016b). These results suggest that caffeine exposure significantly changes the regulatory activity of vascular endothelial cells, which may have important implications regarding the impact of lifestyle in CAD. As caffeine may modulate gene regulatory activity, the resulting impact on gene expression may increase or decrease CAD risk. In addition, we identified novel transcription factors contributing to the regulatory response to caffeine including several NFAT transcription factors, and SREBF2. NFAT transcription factors are largely known for their role in the Ca2+/NFAT signaling pathway, where Ca2+ binds to calmodulin, stimulating calcineurin, which then causes NFAT factors to localize in the nucleus (Crabtree and Olson, 2002; Klee et al., 1998). Caffeine is known to cause an increase in Ca2+ in human aortic endothelial cells (Corda et al., 1995), so it is understandable that we find these factors enriched for being within targets that respond to caffeine exposure. SREBF2, also known as SREBP2, is involved in sterol homeostasis (Horton et al., 2003). This result implies these novel transcription factors important for the regulatory response to caffeine may also contribute to understanding the role of caffeine in CAD risk. This coincides with findings that caffeine exposure can alter expression of genes, including those for transcription factors in mouse cardiomyocytes (Fang et al., 2014). Another study aimed to uncover mechanisms relevant to CVD upon caffeine exposure and found that caffeine inhibits the transcription factor SREBP2, which causes an overall protective effect against CVD (Lebeau et al., 2022). These results coincide with our findings.

Noncoding regions of the genome contain regulatory variants that modulate gene expression. In this study, we identify and characterize over 600 variants exhibiting ASE. Numerous noncoding variants have been implicated in CAD risk via GWAS (Hartmann et al., 2022; Kessler and Schunkert, 2021; Koyama et al., 2020; Nikpay et al., 2015; Temprano‐Sagrera et al., 2022; van der Harst and Verweij, 2018), but they are generally uncharacterized. Few lead noncoding variants have been thoroughly investigated. One of these led the authors to propose and validate a molecular mechanism connecting expression of the EDN1 gene to the phenotypic outcome (Gupta et al., 2017; Wang and Musunuru, 2018). The specific mechanisms that detail how noncoding variants contribute to CAD will be critical in understanding CAD risk and ultimately developing clinical treatments. While understanding various genetic risk factors for CAD is important, GxE for these variants also have an impact on phenotype and have not been widely studied.

Since previous studies have shown that GxE-eQTL can modulate complex disease risk, we expect that GxE detected in our assay may be relevant to CAD (Alasoo et al., 2019; Alasoo et al., 2018; Barreiro et al., 2012; Çalışkan et al., 2015; Fairfax et al., 2014; Findley et al., 2021; Huang et al., 2020; Kim-Hellmuth et al., 2017; Knowles et al., 2018; Lee et al., 2014; Mangravite et al., 2013; Manry et al., 2017; Maranville et al., 2011; Nédélec et al., 2016; Quach et al., 2016). We tested for cASE, which occurs when ASE are only significant in one condition, or significantly different between the two conditions. This analysis identifies GxE which are important in understanding disease risk while accounting for genetic and environmental context. We identified 6 variants that regulate the gene expression response to caffeine and demonstrated that context-aware MPRAs can be used to dissect molecular mechanisms underlying cardiovascular health.

By fine-mapping artery eQTLs and combining the data collected from our assay with preexisting annotations, we produced potential mechanisms for two cASE variants through altered transcription factor expression and binding in response to caffeine. Our results indicated that both genetic and environmental factors are important in determining risk, and that the interaction between these factors can be informative to mechanisms and phenotypic consequences. Importantly, by utilizing multiple functional annotations, we are able to identify variants that may be relevant to disease but did not reach genome-wide significance in GWAS, possibly because of their context-specific effects. By studying different environmental contexts, we can identify that, in these instances, the presence of caffeine can impact the risk of poor cardiovascular health outcomes. If environmental context was not considered and this work was conducted solely in the control condition, the caffeine modulatory effect on risk would have been missed.

Although we investigate GxE for caffeine in vascular endothelial cells, our experimental approach can be applied to various different complex diseases and their relevant cell types and treatments. To further validate our work, genome-editing tools could be used to investigate the effect of these variants in their native chromatin context. Additional validation could include allele-specific and condition-specific transcription factor binding assays (such as electrophoretic mobility shift assays) for the fine-mapped variants.

Our study demonstrates the importance of considering environmental contexts when investigating gene regulatory activity as we identify several thousand instances of GxE in our library of candidate regulatory variants. Our data, combined with preexisting annotations, allowed us to identify transcription factors involved in GxE in caffeine and describe specific potential molecular mechanisms for some of these GxE. Our results provide important insights into the molecular regulatory effect of caffeine exposure and GxE for caffeine in vascular endothelial cells.

Materials and methods

Cell culture

Request a detailed protocol

Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Cat# CC-2517-0000315288). Cells were cultured at 37°C with 5% CO2 and seeded at 5000 cells/cm2. EGM-2 growth medium (Lonza) was used to culture the cells.

Treatment

Request a detailed protocol

Treatment concentration was the same as used in previous studies (Findley et al., 2019; Moyerbrailean et al., 2016b). We used a caffeine concentration of 1.16 × 10–3 M. In addition, water was used as a vehicle control as that was the solvent used to prepare the caffeine treatment.

BiT-STARR-Seq library design

Request a detailed protocol

We designed 43,556 target regulatory regions each containing an SNP in the middle and with a total length of 200 nucleotides. This set of targets corresponds to 87,112 constructs each containing only one of two alleles at the test SNP. Additionally, each construct can be integrated in the forward or reverse orientation, leading to a maximum of 174,224 constructs in either direction. Please also see below for a description of how we use library-related terms throughout the article. The library used is the same as reported in Kalita et al., 2018. Briefly, the library of target regulatory sequences consisted of several categories of regulatory variants, including eQTLs (Innocenti et al., 2011; Wen et al., 2015), SNPs predicted to disrupt transcription factor binding (centiSNPs) (Moyerbrailean et al., 2016a), and SNPs associated with complex traits in GWAS (Pickrell, 2014). Negative controls that were not predicted to have a regulatory effect were also included in the library (Moyerbrailean et al., 2016a). It is important to note that these negative controls are only predicted not to have a regulatory effect via computational annotation (Moyerbrailean et al., 2016a), so they may not be representative of true negative controls. This is why we largely do not utilize these SNPs as negative controls within our analyses. Our predictions of regulatory activity also did not account for environmental context, thus these sequences are also not suited to annotate our cASE results.

  • SNP (n = 43,556): Refers to a genetic variant tested for allelic effects on gene regulation.

  • Target (n = 43,556): 200-nucleotide-long oligonucleotide sequence that contains the test SNP in the middle of the target.

  • Construct (n = 87,112): Synthesized 200-nucleotide-long oligonucleotide sequence that contains only one of the two possible alleles at the test SNP. Each target corresponds to two constructs.

  • Direction: Constructs can integrate in either the forward or reverse direction relative to the direction of transcription in the BiT-STARR-Seq plasmid. Therefore, two directions are possible for each construct.

  • SNP/direction pair (n = 87,112): An SNP tested for allelic effects on gene regulation contrasting the expression of two constructs that are integrated in the same direction. All statistical tests are performed at this level, testing in each direction separately.

BiT-STARR-Seq experiments

Request a detailed protocol

Oligonucleotides were synthesized and used to create a DNA plasmid library, which was sequenced and used as a subsequent input for the ASE analysis. The DNA library was transfected into HUVECs using the Lonza Nucleofector X platform. Cells were electroporated using the DS-120 setting with primary cell solution P5. Caffeine was added at 1.16 × 10–3 M after transfection. Cells were incubated for 24 hr and lysed. We completed 6 replicates per treatment condition (caffeine and the water vehicle control) or 12 replicates in total.

Library preparation and sequencing

Request a detailed protocol

RNA was extracted using the RNeasy Plus Mini kit (QIAGEN, Cat# 74136). A cDNA library was prepared using the Superscript III First-Strand Synthesis kit (Invitrogen, Cat# 18080-400). Sequencing was completed using the Illumina Nextseq 500 to generate 125 cycles for read 1, 30 cycles for read 2, 8 cycles for the fixed multiplexing index 2, and 10 cycles for index 1 (variable barcode). The average sequencing depth per library was 39,235,611 reads, for a total of 470,827,333 reads (Figure 1—figure supplement 1, Supplementary file 7).

Processing sequence data

Request a detailed protocol

To analyze the RNA-seq data, we began by demultiplexing our data using the bcl2fastq software to create demultiplexed FASTQ files. We then aligned to hg19 using HISAT2. Afterward, we applied a filter to ensure the UMIs present match the expected UMI pattern (RDHBVDHBVD). Reads with short UMIs or those that do not match the expected sequence were removed. The resulting BAM files were then deduplicated using UMItools. We ran samtools mpileup followed by bcftools query to output read counts per each allele/direction combination.

Differential activity analysis

Request a detailed protocol

To test for a molecular response to caffeine, we used the R package DESeq2 (Love et al., 2014). To determine which model would best test for a molecular response to caffeine, we completed principal component analysis to identify major sources of variation. We identified that the first PC clearly represented allelic effects (Figure 2—figure supplement 2, also see Figure 3—figure supplements 1 and 3), thus we included allele (reference or alternate) as part of our model. Our model tested the effect of treatment, correcting for allele (~allele + treatment), as we observed a strong allelic effect. We ran DESeq2 for each direction (see Figure 2—figure supplement 1) as the library contained motifs in both the forward and reverse orientations within separate target sequences. We considered targets as significant with Benjamini–Hochberg FDR <10%.

ASE analysis

Request a detailed protocol

To test for ASE, we utilized the R package quantitative allele-specific analysis of reads (QuASAR-MPRA) (Kalita et al., 2017). QuASAR-MPRA is an extension of the QuASAR package which allows for analysis of barcoded MPRA data. QuASAR-MPRA uses a beta-binomial model and accounts for uneven initial allelic proportions present in the DNA library. We used the fitQuasarMpra() function to test for ASE in each experiment separately, estimating the ASE effect and its standard error. For each SNP/direction pair, we meta-analyzed the effect size using a weighted mean utilizing inverse-variance weighting for each condition separately. The z-score for each SNP-direction pair is subsequently calculated as the meta-analyzed effect size minus the DNA proportion, divided by the meta-analyzed standard error of the effect size. We then required each identifier to be within four or greater replicates (out of the six total replicates) and performed multiple test correction using the Benjamini–Hochberg procedure. Significant ASE was then defined as having an FDR <10%.

cASE analysis

Request a detailed protocol

To test for cASE, we used a method previously developed by our lab called differential allele-specific test, or ΔAST. The calculation for this parameter ΔZ is provided in Moyerbrailean et al., 2016a as well as below. The QuASAR-MPRA package outputs betas for the treatment (βT) and the control (βC), as well as the standard error (se) for both groups, which are used to calculate a Z score for each condition independently (βse). To contrast ASE between conditions we define the cASE statistic (ΔZ)2 , as (ΔZ)2 = (ZT - ZC)2 /2. From this (ΔZ)2 statistic, we used the genomic control procedure (Devlin et al., 2001; Devlin and Roeder, 1999) to calibrate the median χ2 to the expected value and we calculated the p-values using the χ2 distribution. We then used the p.adjust() function to perform multiple test correction using the Benjamini–Hochberg procedure. Significant cASE was then defined as having an FDR<5%.

Motif enrichment analysis

Request a detailed protocol

The motif scan was completed using the PWMScan tool, using all PWMs within the JASPAR (Castro-Mondragon et al., 2022) 2022 CORE database (838 motifs). A threshold of -t 10 (base 2) was used for the motif scan, which was restricted to the regions of our designed targets. Once the scan was complete, motifs that were present less than 100 times in the library were removed. For differentially active targets in response to caffeine, 222 motifs passed this filter. For motifs containing ASE variants, 359 motifs passed this filter. For motifs containing cASE variants, 417 motifs passed the filter. A test of proportion (prop.test() in R) was performed per each transcription factor, where the null proportion was the total number of significant targets/variants containing/within motifs (differentially active target, ASE or cASE) divided by the total number of nonsignificant targets/variants containing/within motifs. The test was done per motif, where the proportion being tested is the same as the null proportion, but conducted per motif rather than across all motifs. The related calculations are shown below:

  • Expected null proportion = na/nb

  • Observed motif proportion = nc/nd

  • na = number of targets/variants of interest containing/within any motif

  • nb = number of targets/variants containing/within any motif

  • nc = number of targets/variants of interest containing/within specific motif

  • nd = number of targets/variants containing/within specific motif

ASE (FDR <10%) and cASE (p<0.0215) were considered significant. For follow-up analyses of cASE features, we relaxed the significance threshold to nominal p-value <0.0215.

Open chromatin region enrichment analysis

Request a detailed protocol

To test if certain variants were within open chromatin regions, we obtained the list of differentially accessible regions tested in Findley et al., 2019. We considered any accessible region (annotated as differentially accessible or not). Bedtools bed intersect tool was used to complete the overlap with the appropriate datasets (DESeq2, ASE, or cASE results), resulting in a list of targets or SNPs that were within open chromatin regions. This annotation was then used to complete the Fisher’s exact test. Enrichments for significant ASE or cASE variants were performed separately.

Artery eQTL enrichment analysis

Request a detailed protocol

To determine if certain variants were artery eQTLs, we obtained GTEx v8 (Castro-Mondragon et al., 2022) data for aorta, coronary, and tibial artery tissues. We then intersected the list of variants of interest with the list of artery eQTLs. To determine if artery eQTLs were within differentially active targets, bedtools intersect was used, resulting in a list of targets that contained artery eQTLs. We further subset this list to variants within open chromatin regions (see previous section). This annotation was then used to complete the Fisher’s exact test. Enrichments for significant ASE or cASE variants were performed separately.

Fine-mapping analysis with DAP-G

Request a detailed protocol

Based on a previous study (Findley et al., 2019), we define caffeine response factors as transcription factors with motifs that were significantly enriched or depleted in differentially accessible chromatin after treatment with caffeine. We annotated genetic variants into two categories: (1) genetic variants in motifs for response factors and (2) genetic variants in motifs for transcription factors that are not caffeine response factors. By integration of these genetic variants annotation, we estimated the probability of each SNP regulating gene expression in a Bayesian hierarchical model using TORUS (Wen, 2016). These probabilities are then used in DAP-G (Zhang et al., 2020) to fine-map eQTLs from all three artery tissues in GTEx V8. A total of 364,427,888 eQTLs were fine-mapped across three artery tissues. We filtered for a posterior inclusion probability of >0.9.

Identification of putative causal genes

Request a detailed protocol

To better understand how cASE variants may impact traits related to cardiovascular health, we performed colocalization analysis of the causal GWAS variants with eQTLs using fastENLOC (Wen et al., 2017) by integration of fine-mapped eQTLs in the three artery tissues (see above section) and fine-mapped GWAS signals for CAD and hypertension. We fine-mapped GWAS using DAP (Wen, 2016). From fastENLOC, we obtained the gene locus-level colocalization probability for each gene which is used to evaluate how the gene is associated with complex traits or diseases. Intuitively, colocalization analysis identified the overlap of causal eQTLs and GWAS hits. However, it lacked the sensitivity due to the failure in distinguishing between the vertical pleiotropy (genetic effects on traits mediated by gene expression) and horizontal pleiotropy (independent effects on gene expression and traits) (Okamoto et al., 2023). To overcome the limitations in a single approach, we combined the evidence from colocalization and TWAS to estimate the probability of putative causal genes using the R package INTACT (Okamoto et al., 2023). Here, the TWAS data we utilized were from PTWAS (Zhang et al., 2020). We determined putative causal genes with FDR < 10%. We then identified variants regulating these putative causal genes using the DAP-G fine-mapping results, requiring a SNP-level colocalization probability >0.5, with no threshold on PIP (Supplementary file 6).

Data availability

FASTQ files and read count data are available at the GEO accession number GSE221514. Supplemental files are available at https://doi.org/10.5281/zenodo.7327508.

The following data sets were generated
    1. Boye C
    2. Kalita C
    3. Findley A
    4. Alazizi A
    5. Wei J
    6. Wen X
    7. Luca F
    8. Pique-Regi R
    (2024) NCBI Gene Expression Omnibus
    ID GSE221514. Characterization of caffeine response regulatory variants in vascular endothelial cells.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221514
    1. Boye C
    2. Kalita C
    3. Findley A
    4. Alazizi A
    5. Wei J
    6. Wen X
    7. Pique-Regi R
    8. Luca F
    (2024) Zenodo
    Characterization of caffeine response regulatory variants in vascular endothelial cells.
    https://doi.org/10.5281/zenodo.7327508
The following previously published data sets were used

References

  7. Book
    1. Brown JC
    2. Gerhardt TE
    3. Kwon E
    (2022)
    Risk Factors For Coronary Artery DiseaseStatPearls
    Treasure Island: StatPearls Publishing.
    1. Fryar CD
    2. Chen TC
    3. Li X
    (2012)
    Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010
    NCHS Data Brief 1:1–8.
    1. Hadi HAR
    2. Carr CS
    3. Al Suwaidi J
    (2005)
    Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome
    Vascular Health and Risk Management 1:183–198.
    1. Kim-Hellmuth S
    2. Aguet F
    3. Oliva M
    4. Muñoz-Aguirre M
    5. Kasela S
    6. Wucher V
    7. Castel SE
    8. Hamel AR
    9. Viñuela A
    10. Roberts AL
    11. Mangul S
    12. Wen X
    13. Wang G
    14. Barbeira AN
    15. Garrido-Martín D
    16. Nadel BB
    17. Zou Y
    18. Bonazzola R
    19. Quan J
    20. Brown A
    21. Martinez-Perez A
    22. Soria JM
    23. Getz G
    24. Dermitzakis ET
    25. Small KS
    26. Stephens M
    27. Xi HS
    28. Im HK
    29. Guigó R
    30. Segrè AV
    31. Stranger BE
    32. Ardlie KG
    33. Lappalainen T
    34. Aguet F
    35. Anand S
    36. Ardlie KG
    37. Gabriel S
    38. Getz GA
    39. Graubert A
    40. Hadley K
    41. Handsaker RE
    42. Huang KH
    43. Kashin S
    44. Li X
    45. MacArthur DG
    46. Meier SR
    47. Nedzel JL
    48. Nguyen DT
    49. Segrè AV
    50. Todres E
    51. Balliu B
    52. Barbeira AN
    53. Battle A
    54. Bonazzola R
    55. Brown A
    56. Brown CD
    57. Castel SE
    58. Conrad DF
    59. Cotter DJ
    60. Cox N
    61. Das S
    62. de Goede OM
    63. Dermitzakis ET
    64. Einson J
    65. Engelhardt BE
    66. Eskin E
    67. Eulalio TY
    68. Ferraro NM
    69. Flynn ED
    70. Fresard L
    71. Gamazon ER
    72. Garrido-Martín D
    73. Gay NR
    74. Gloudemans MJ
    75. Guigó R
    76. Hame AR
    77. He Y
    78. Hoffman PJ
    79. Hormozdiari F
    80. Hou L
    81. Im HK
    82. Jo B
    83. Kasela S
    84. Kellis M
    85. Kim-Hellmuth S
    86. Kwong A
    87. Lappalainen T
    88. Li X
    89. Liang Y
    90. Mangul S
    91. Mohammadi P
    92. Montgomery SB
    93. Muñoz-Aguirre M
    94. Nachun DC
    95. Nobel AB
    96. Oliva M
    97. Park Y
    98. Park Y
    99. Parsana P
    100. Rao AS
    101. Reverter F
    102. Rouhana JM
    103. Sabatti C
    104. Saha A
    105. Stephens M
    106. Stranger BE
    107. Strober BJ
    108. Teran NA
    109. Viñuela A
    110. Wang G
    111. Wen X
    112. Wright F
    113. Wucher V
    114. Zou Y
    115. Ferreira PG
    116. Li G
    117. Melé M
    118. Yeger-Lotem E
    119. Barcus ME
    120. Bradbury D
    121. Krubit T
    122. McLean JA
    123. Qi L
    124. Robinson K
    125. Roche NV
    126. Smith AM
    127. Sobin L
    128. Tabor DE
    129. Undale A
    130. Bridge J
    131. Brigham LE
    132. Foster BA
    133. Gillard BM
    134. Hasz R
    135. Hunter M
    136. Johns C
    137. Johnson M
    138. Karasik E
    139. Kopen G
    140. Leinweber WF
    141. McDonald A
    142. Moser MT
    143. Myer K
    144. Ramsey KD
    145. Roe B
    146. Shad S
    147. Thomas JA
    148. Walters G
    149. Washington M
    150. Wheeler J
    151. Jewell SD
    152. Rohrer DC
    153. Valley DR
    154. Davis DA
    155. Mash DC
    156. Branton PA
    157. Barker LK
    158. Gardiner HM
    159. Mosavel M
    160. Siminoff LA
    161. Flicek P
    162. Haeussler M
    163. Juettemann T
    164. Kent WJ
    165. Lee CM
    166. Powell CC
    167. Rosenbloom KR
    168. Ruffier M
    169. Sheppard D
    170. Taylor K
    171. Trevanion SJ
    172. Zerbino DR
    173. Abell NS
    174. Akey J
    175. Chen L
    176. Demanelis K
    177. Doherty JA
    178. Feinberg AP
    179. Hansen KD
    180. Hickey PF
    181. Jasmine F
    182. Jiang L
    183. Kaul R
    184. Kibriya MG
    185. Li JB
    186. Li Q
    187. Lin S
    188. Linder SE
    189. Pierce BL
    190. Rizzardi LF
    191. Skol AD
    192. Smith KS
    193. Snyder M
    194. Stamatoyannopoulos J
    195. Tang H
    196. Wang M
    197. Carithers LJ
    198. Guan P
    199. Koester SE
    200. Little AR
    201. Moore HM
    202. Nierras CR
    203. Rao AK
    204. Vaught JB
    205. Volpi S
    206. GTEx Consortium
    (2020) Cell type–specific genetic regulation of gene expression across human tissues
    Science 369:aaz8528.
    https://doi.org/10.1126/science.aaz8528
    1. Nikpay M
    2. Goel A
    3. Won H-H
    4. Hall LM
    5. Willenborg C
    6. Kanoni S
    7. Saleheen D
    8. Kyriakou T
    9. Nelson CP
    10. Hopewell JC
    11. Webb TR
    12. Zeng L
    13. Dehghan A
    14. Alver M
    15. Armasu SM
    16. Auro K
    17. Bjonnes A
    18. Chasman DI
    19. Chen S
    20. Ford I
    21. Franceschini N
    22. Gieger C
    23. Grace C
    24. Gustafsson S
    25. Huang J
    26. Hwang S-J
    27. Kim YK
    28. Kleber ME
    29. Lau KW
    30. Lu X
    31. Lu Y
    32. Lyytikäinen L-P
    33. Mihailov E
    34. Morrison AC
    35. Pervjakova N
    36. Qu L
    37. Rose LM
    38. Salfati E
    39. Saxena R
    40. Scholz M
    41. Smith AV
    42. Tikkanen E
    43. Uitterlinden A
    44. Yang X
    45. Zhang W
    46. Zhao W
    47. de Andrade M
    48. de Vries PS
    49. van Zuydam NR
    50. Anand SS
    51. Bertram L
    52. Beutner F
    53. Dedoussis G
    54. Frossard P
    55. Gauguier D
    56. Goodall AH
    57. Gottesman O
    58. Haber M
    59. Han B-G
    60. Huang J
    61. Jalilzadeh S
    62. Kessler T
    63. König IR
    64. Lannfelt L
    65. Lieb W
    66. Lind L
    67. Lindgren CM
    68. Lokki M-L
    69. Magnusson PK
    70. Mallick NH
    71. Mehra N
    72. Meitinger T
    73. Memon FUR
    74. Morris AP
    75. Nieminen MS
    76. Pedersen NL
    77. Peters A
    78. Rallidis LS
    79. Rasheed A
    80. Samuel M
    81. Shah SH
    82. Sinisalo J
    83. Stirrups KE
    84. Trompet S
    85. Wang L
    86. Zaman KS
    87. Ardissino D
    88. Boerwinkle E
    89. Borecki IB
    90. Bottinger EP
    91. Buring JE
    92. Chambers JC
    93. Collins R
    94. Cupples LA
    95. Danesh J
    96. Demuth I
    97. Elosua R
    98. Epstein SE
    99. Esko T
    100. Feitosa MF
    101. Franco OH
    102. Franzosi MG
    103. Granger CB
    104. Gu D
    105. Gudnason V
    106. Hall AS
    107. Hamsten A
    108. Harris TB
    109. Hazen SL
    110. Hengstenberg C
    111. Hofman A
    112. Ingelsson E
    113. Iribarren C
    114. Jukema JW
    115. Karhunen PJ
    116. Kim B-J
    117. Kooner JS
    118. Kullo IJ
    119. Lehtimäki T
    120. Loos RJF
    121. Melander O
    122. Metspalu A
    123. März W
    124. Palmer CN
    125. Perola M
    126. Quertermous T
    127. Rader DJ
    128. Ridker PM
    129. Ripatti S
    130. Roberts R
    131. Salomaa V
    132. Sanghera DK
    133. Schwartz SM
    134. Seedorf U
    135. Stewart AF
    136. Stott DJ
    137. Thiery J
    138. Zalloua PA
    139. O’Donnell CJ
    140. Reilly MP
    141. Assimes TL
    142. Thompson JR
    143. Erdmann J
    144. Clarke R
    145. Watkins H
    146. Kathiresan S
    147. McPherson R
    148. Deloukas P
    149. Schunkert H
    150. Samani NJ
    151. Farrall M
    (2015) A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease
    Nature Genetics 47:1121–1130.
    https://doi.org/10.1038/ng.3396
    1. Temprano‐Sagrera G
    2. Sitlani CM
    3. Bone WP
    4. Martin‐Bornez M
    5. Voight BF
    6. Morrison AC
    7. Damrauer SM
    8. de Vries PS
    9. Smith NL
    10. Sabater‐Lleal M
    11. Dehghan A
    12. Heath AS
    13. Morrison AC
    14. Reiner AP
    15. Johnson A
    16. Richmond A
    17. Peters A
    18. van Hylckama Vlieg A
    19. McKnight B
    20. Psaty BM
    21. Hayward C
    22. Ward‐Caviness C
    23. O’Donnell C
    24. Chasman D
    25. Strachan DP
    26. Tregouet DA
    27. Mook‐Kanamori D
    28. Gill D
    29. Thibord F
    30. Asselbergs FW
    31. Leebeek FWG
    32. Rosendaal FR
    33. Davies G
    34. Homuth G
    35. Temprano G
    36. Campbell H
    37. Taylor HA
    38. Bressler J
    39. Huffman JE
    40. Rotter JI
    41. Yao J
    42. Wilson JF
    43. Bis JC
    44. Hahn JM
    45. Desch KC
    46. Wiggins KL
    47. Raffield LM
    48. Bielak LF
    49. Yanek LR
    50. Kleber ME
    51. Sabater‐Lleal M
    52. Mueller M
    53. Kavousi M
    54. Mangino M
    55. Liu M
    56. Brown MR
    57. Conomos MP
    58. Jhun M
    59. Chen M
    60. de Maat MPM
    61. Pankratz N
    62. Smith NL
    63. Peyser PA
    64. Elliot P
    65. de Vries PS
    66. Wei P
    67. Wild PS
    68. Morange PE
    69. van der Harst P
    70. Yang Q
    71. Le N
    72. Marioni R
    73. Li R
    74. Damrauer SM
    75. Cox SR
    76. Trompet S
    77. Felix SB
    78. Völker U
    79. Tang W
    80. Koenig W
    81. Jukema JW
    82. Guo X
    83. Lindstrom S
    84. Wang L
    85. Smith EN
    86. Gordon W
    87. van Hylckama Vlieg A
    88. de Andrade M
    89. Brody JA
    90. Pattee JW
    91. Haessler J
    92. Brumpton BM
    93. Chasman DI
    94. Suchon P
    95. Chen M
    96. Turman C
    97. Germain M
    98. Wiggins KL
    99. MacDonald J
    100. Braekkan SK
    101. Armasu SM
    102. Pankratz N
    103. Jackson RD
    104. Nielsen JB
    105. Giulianini F
    106. Puurunen MK
    107. Ibrahim M
    108. Heckbert SR
    109. Bammler TK
    110. Frazer KA
    111. McCauley BM
    112. Taylor K
    113. Pankow JS
    114. Reiner AP
    115. Gabrielsen ME
    116. Deleuze J
    117. O’Donnell CJ
    118. Kim J
    119. McKnight B
    120. Kraft P
    121. Hansen J
    122. Rosendaal FR
    123. Heit JA
    124. Psaty BM
    125. Tang W
    126. Kooperberg C
    127. Hveem K
    128. Ridker PM
    129. Morange P
    130. Johnson AD
    131. Kabrhel C
    132. Trégouët D
    133. Smith NL
    134. Malik R
    135. Chauhan G
    136. Traylor M
    137. Sargurupremraj M
    138. Okada Y
    139. Mishra A
    140. Rutten‐Jacobs L
    141. Giese A
    142. van der Laan SW
    143. Gretarsdottir S
    144. Anderson CD
    145. Chong M
    146. Adams HH
    147. Ago T
    148. Almgren P
    149. Amouyel P
    150. Ay H
    151. Bartz TM
    152. Benavente OR
    153. Bevan S
    154. Boncoraglio GB
    155. Brown RD
    156. Butterworth AS
    157. Carrera C
    158. Carty CL
    159. Chasman DI
    160. Chen W
    161. Cole JW
    162. Correa A
    163. Cotlarciuc I
    164. Cruchaga C
    165. Danesh J
    166. de Bakker PI
    167. DeStefano AL
    168. den Hoed M
    169. Duan Q
    170. Engelter ST
    171. Falcone GJ
    172. Gottesman RF
    173. Grewal RP
    174. Gudnason V
    175. Gustafsson S
    176. Haessler J
    177. Harris TB
    178. Hassan A
    179. Havulinna AS
    180. Heckbert SR
    181. Holliday EG
    182. Howard G
    183. Hsu F
    184. Hyacinth HI
    185. Arfan Ikram M
    186. Ingelsson E
    187. Irvin MR
    188. Jian X
    189. Jiménez‐Conde J
    190. Johnson JA
    191. Jukema JW
    192. Kanai M
    193. Keene KL
    194. Kissela BM
    195. Kleindorfer DO
    196. Kooperberg C
    197. Kubo M
    198. Lange LA
    199. Langefeld CD
    200. Langenberg C
    201. Launer LJ
    202. Lee J
    203. Lemmens R
    204. Leys D
    205. Lewis CM
    206. Lin W
    207. Lindgren AG
    208. Lorentzen E
    209. Magnusson PK
    210. Maguire J
    211. Manichaikul A
    212. McArdle PF
    213. Meschia JF
    214. Mitchell BD
    215. Mosley TH
    216. Nalls MA
    217. Ninomiya T
    218. O’Donnell MJ
    219. Psaty BM
    220. Pulit SL
    221. Rannikmäe K
    222. Reiner AP
    223. Rexrode KM
    224. Rice K
    225. Rich SS
    226. Ridker PM
    227. Rost NS
    228. Rothwell PM
    229. Rotter JI
    230. Rundek T
    231. Sacco RL
    232. Sakaue S
    233. Sale MM
    234. Salomaa V
    235. Sapkota BR
    236. Schmidt R
    237. Schmidt CO
    238. Schminke U
    239. Sharma P
    240. Slowik A
    241. Sudlow CL
    242. Tanislav C
    243. Tatlisumak T
    244. Taylor KD
    245. Thijs VN
    246. Thorleifsson G
    247. Thorsteinsdottir U
    248. Tiedt S
    249. Trompet S
    250. Tzourio C
    251. van Duijn CM
    252. Walters M
    253. Wareham NJ
    254. Wassertheil‐Smoller S
    255. Wilson JG
    256. Wiggins KL
    257. Yang Q
    258. Yusuf S
    259. Amin N
    260. Aparicio HS
    261. Arnett DK
    262. Attia J
    263. Beiser AS
    264. Berr C
    265. Buring JE
    266. Bustamante M
    267. Caso V
    268. Cheng Y
    269. Hoan Choi S
    270. Chowhan A
    271. Cullell N
    272. Dartigues J
    273. Delavaran H
    274. Delgado P
    275. Dörr M
    276. Engström G
    277. Ford I
    278. Gurpreet WS
    279. Hamsten A
    280. Heitsch L
    281. Hozawa A
    282. Ibanez L
    283. Ilinca A
    284. Ingelsson M
    285. Iwasaki M
    286. Jackson RD
    287. Jood K
    288. Jousilahti P
    289. Kaffashian S
    290. Kalra L
    291. Kamouchi M
    292. Kitazono T
    293. Kjartansson O
    294. Kloss M
    295. Koudstaal PJ
    296. Krupinski J
    297. Labovitz DL
    298. Laurie CC
    299. Levi CR
    300. Li L
    301. Lind L
    302. Lindgren CM
    303. Lioutas V
    304. Mei Liu Y
    305. Lopez OL
    306. Makoto H
    307. Martinez‐Majander N
    308. Matsuda K
    309. Minegishi N
    310. Montaner J
    311. Morris AP
    312. Muiño E
    313. Müller‐Nurasyid M
    314. Norrving B
    315. Ogishima S
    316. Parati EA
    317. Reddy Peddareddygari L
    318. Pedersen NL
    319. Pera J
    320. Perola M
    321. Pezzini A
    322. Pileggi S
    323. Rabionet R
    324. Riba‐Llena I
    325. Ribasés M
    326. Romero JR
    327. Roquer J
    328. Rudd AG
    329. Sarin A
    330. Sarju R
    331. Sarnowski C
    332. Sasaki M
    333. Satizabal CL
    334. Satoh M
    335. Sattar N
    336. Sawada N
    337. Sibolt G
    338. Sigurdsson Á
    339. Smith A
    340. Sobue K
    341. Soriano‐Tárraga C
    342. Stanne T
    343. Colin Stine O
    344. Stott DJ
    345. Strauch K
    346. Takai T
    347. Tanaka H
    348. Tanno K
    349. Teumer A
    350. Tomppo L
    351. Torres‐Aguila NP
    352. Touze E
    353. Tsugane S
    354. Uitterlinden AG
    355. Valdimarsson EM
    356. van der Lee SJ
    357. Völzke H
    358. Wakai K
    359. Weir D
    360. Williams SR
    361. Wolfe CD
    362. Wong Q
    363. Xu H
    364. Yamaji T
    365. Sanghera DK
    366. Melander O
    367. Jern C
    368. Strbian D
    369. Fernandez‐Cadenas I
    370. Longstreth WT
    371. Rolfs A
    372. Hata J
    373. Woo D
    374. Rosand J
    375. Pare G
    376. Hopewell JC
    377. Saleheen D
    378. Stefansson K
    379. Worrall BB
    380. Kittner SJ
    381. Seshadri S
    382. Fornage M
    383. Markus HS
    384. Howson JM
    385. Kamatani Y
    386. Debette S
    387. Dichgans M
    (2022) Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
    Journal of Thrombosis and Haemostasis 20:1331–1349.
    https://doi.org/10.1111/jth.15698

Article and author information

Author details

  1. Carly Boye

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    Contribution
    Data curation, Formal analysis, Validation, Visualization, Writing – original draft, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9142-0240

  2. Cynthia A Kalita

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    Contribution
    Data curation, Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  3. Anthony S Findley

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    Contribution
    Data curation, Formal analysis, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9922-3076

  4. Adnan Alazizi

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  5. Julong Wei

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    Contribution
    Formal analysis, Visualization, Writing – original draft, Writing – review and editing
    Competing interests
    No competing interests declared

  6. Xiaoquan Wen

    Department of Biostatistics, University of Michigan, Ann Arbor, United States
    Contribution
    Software, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  7. Roger Pique-Regi

    1. Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    2. Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    Contribution
    Conceptualization, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    rpique@wayne.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1262-2275

  8. Francesca Luca

    1. Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    2. Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    3. Department of Biology, University of Rome Tor Vergata, Rome, Italy
    Contribution
    Conceptualization, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    fluca@wayne.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8252-9052

Funding

National Institute of General Medical Sciences (R01GM109215)

  • Francesca Luca
  • Roger Pique-Regi

National Institute of Environmental Health Sciences (R01ES033634)

  • Francesca Luca
  • Roger Pique-Regi
  • Xiaoquan Wen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank the members of the Luca and Pique-Regi laboratories for helpful comments and discussions.

Version history

  1. Preprint posted: November 24, 2022 (view preprint)
  2. Received: November 30, 2022
  3. Accepted: February 8, 2024
  4. Accepted Manuscript published: February 9, 2024 (version 1)
  5. Version of Record published: February 28, 2024 (version 2)

Copyright

© 2024, Boye et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 311
    views
  • 52
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carly Boye
  2. Cynthia A Kalita
  3. Anthony S Findley
  4. Adnan Alazizi
  5. Julong Wei
  6. Xiaoquan Wen
  7. Roger Pique-Regi
  8. Francesca Luca
(2024)
Characterization of caffeine response regulatory variants in vascular endothelial cells
eLife 13:e85235.
https://doi.org/10.7554/eLife.85235

Share this article

https://doi.org/10.7554/eLife.85235

Categories and tags

Research organism

Further reading

    1. Genetics and Genomics

    Uncharacterized yeast gene YBR238C, an effector of TORC1 signaling in a mitochondrial feedback loop, accelerates cellular aging via HAP4- and RMD9-dependent mechanisms

    Mohammad Alfatah, Jolyn Jia Jia Lim ... Frank Eisenhaber
    Research Article

    Uncovering the regulators of cellular aging will unravel the complexity of aging biology and identify potential therapeutic interventions to delay the onset and progress of chronic, aging-related diseases. In this work, we systematically compared genesets involved in regulating the lifespan of Saccharomyces cerevisiae (a powerful model organism to study the cellular aging of humans) and those with expression changes under rapamycin treatment. Among the functionally uncharacterized genes in the overlap set, YBR238C stood out as the only one downregulated by rapamycin and with an increased chronological and replicative lifespan upon deletion. We show that YBR238C and its paralog RMD9 oppositely affect mitochondria and aging. YBR238C deletion increases the cellular lifespan by enhancing mitochondrial function. Its overexpression accelerates cellular aging via mitochondrial dysfunction. We find that the phenotypic effect of YBR238C is largely explained by HAP4- and RMD9-dependent mechanisms. Furthermore, we find that genetic- or chemical-based induction of mitochondrial dysfunction increases TORC1 (Target of Rapamycin Complex 1) activity that, subsequently, accelerates cellular aging. Notably, TORC1 inhibition by rapamycin (or deletion of YBR238C) improves the shortened lifespan under these mitochondrial dysfunction conditions in yeast and human cells. The growth of mutant cells (a proxy of TORC1 activity) with enhanced mitochondrial function is sensitive to rapamycin whereas the growth of defective mitochondrial mutants is largely resistant to rapamycin compared to wild type. Our findings demonstrate a feedback loop between TORC1 and mitochondria (the TORC1–MItochondria–TORC1 (TOMITO) signaling process) that regulates cellular aging processes. Hereby, YBR238C is an effector of TORC1 modulating mitochondrial function.

    1. Genetics and Genomics
    2. Neuroscience

    Metabolic and neurobehavioral disturbances induced by purine recycling deficiency in Drosophila

    Céline Petitgas, Laurent Seugnet ... Serge Birman
    Research Article

    Adenine phosphoribosyltransferase (APRT) and hypoxanthine-guanine phosphoribosyltransferase (HGPRT) are two structurally related enzymes involved in purine recycling in humans. Inherited mutations that suppress HGPRT activity are associated with Lesch–Nyhan disease (LND), a rare X-linked metabolic and neurological disorder in children, characterized by hyperuricemia, dystonia, and compulsive self-injury. To date, no treatment is available for these neurological defects and no animal model recapitulates all symptoms of LND patients. Here, we studied LND-related mechanisms in the fruit fly. By combining enzymatic assays and phylogenetic analysis, we confirm that no HGPRT activity is expressed in Drosophila melanogaster, making the APRT homolog (Aprt) the only purine-recycling enzyme in this organism. Whereas APRT deficiency does not trigger neurological defects in humans, we observed that Drosophila Aprt mutants show both metabolic and neurobehavioral disturbances, including increased uric acid levels, locomotor impairments, sleep alterations, seizure-like behavior, reduced lifespan, and reduction of adenosine signaling and content. Locomotor defects could be rescued by Aprt re-expression in neurons and reproduced by knocking down Aprt selectively in the protocerebral anterior medial (PAM) dopaminergic neurons, the mushroom bodies, or glia subsets. Ingestion of allopurinol rescued uric acid levels in Aprt-deficient mutants but not neurological defects, as is the case in LND patients, while feeding adenosine or N6-methyladenosine (m6A) during development fully rescued the epileptic behavior. Intriguingly, pan-neuronal expression of an LND-associated mutant form of human HGPRT (I42T), but not the wild-type enzyme, resulted in early locomotor defects and seizure in flies, similar to Aprt deficiency. Overall, our results suggest that Drosophila could be used in different ways to better understand LND and seek a cure for this dramatic disease.

    1. Genetics and Genomics

    Mono-methylated histones control PARP-1 in chromatin and transcription

    Gbolahan Bamgbose, Guillaume Bordet ... Alexei Tulin
    Research Article

    PARP-1 is central to transcriptional regulation under both normal and stress conditions, with the governing mechanisms yet to be fully understood. Our biochemical and ChIP-seq-based analyses showed that PARP-1 binds specifically to active histone marks, particularly H4K20me1. We found that H4K20me1 plays a critical role in facilitating PARP-1 binding and the regulation of PARP-1-dependent loci during both development and heat shock stress. Here, we report that the sole H4K20 mono-methylase, pr-set7, and parp-1 Drosophila mutants undergo developmental arrest. RNA-seq analysis showed an absolute correlation between PR-SET7- and PARP-1-dependent loci expression, confirming co-regulation during developmental phases. PARP-1 and PR-SET7 are both essential for activating hsp70 and other heat shock genes during heat stress, with a notable increase of H4K20me1 at their gene body. Mutating pr-set7 disrupts monomethylation of H4K20 along heat shock loci and abolish PARP-1 binding there. These data strongly suggest that H4 monomethylation is a key triggering point in PARP-1 dependent processes in chromatin.